Scarica l'app Stockscreener
12.34
10.67%
1.19
Dopo l'orario di chiusura:
12.31
-0.03
-0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.15
Aprire:
$11.26
Volume 24 ore:
2.62M
Relative Volume:
1.30
Capitalizzazione di mercato:
$564.06M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-14.87
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
+15.87%
1M Prestazione:
+4.05%
6M Prestazione:
-2.99%
1 anno Prestazione:
+112.76%
Intervallo 1D:
$11.18
$12.48
Intervallo di 1 settimana:
$9.53
$12.48
Portata 52W:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
12.34 | 486.79M | 27.10M | -24.31M | -33.33M | -0.83 |
|
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
Millennium Management LLC Acquires 12,285 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
BNP Paribas Financial Markets Reduces Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Two Sigma Investments LP Has $1.64 Million Stake in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bank of America Corp DE Purchases 154,127 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Takes Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Capricor Therapeutics, Inc. (CAPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
(CAPR) Technical Data - news.stocktradersdaily.com
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Announces Equity Incentive Plan By Investing.com - Investing.com South Africa
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock Ne - GuruFocus
CAPR Schedules Conference Call with CFO Bergmann | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Equity Incentive Plan - Investing.com
Capricor Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Connect - ACCESS Newswire
D. E. Shaw & Co. Inc. Purchases New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Janus Henderson Group PLC Acquires New Position in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Cut to “Sell” at Wall Street Zen - Defense World
What is Roth Capital’s Estimate for CAPR Q2 Earnings? - Defense World
Capricor Therapeutics’ Buy Thesis Ahead Of Deramiocel PDUFA Date (NASDAQ:CAPR) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out - ACCESS Newswire
Roth Capital Initiates Coverage on Capricor Therapeutics (NASDAQ:CAPR) - Defense World
Analysts Set Expectations for CAPR FY2026 Earnings - Defense World
Uncertainties Regarding Capricor's CAP-1002 Approval (NASDAQ:CAPR) - Seeking Alpha
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision - Seeking Alpha
Capricor Therapeutics, Inc.’s (CAPR): Analysts See 489% Upside Potential - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Northern Trust Corp Boosts Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Stock (CAPR) Launch Hype Builds on Potential Breakthrough Therapy - Value The Markets
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2025 Earnings Call Transcript - MSN
Roth Capital Initiates Coverage on Capricor Therapeutics With Buy Rating - marketscreener.com
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Capricor Therapeutics (CAPR): Roth Capital Sees Strong Growth Po - GuruFocus
Capricor Therapeutics, Inc. (CAPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by The Manufacturers Life Insurance Company - Defense World
Research Analysts Offer Predictions for CAPR FY2025 Earnings - Defense World
How to Take Advantage of moves in (CAPR) - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Invests $197,000 in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor signals readiness for deramiocel approval with $145M in cash and expanded commercial launch preparations - MSN
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair - simplywall.st
Analysts Are Upgrading Capricor Therapeutics, Inc. (NASDAQ:CAPR) After Its Latest Results - Yahoo Finance
Capricor Therapeutics’ Earnings Call: Optimism Amid Challenges - TipRanks
Capricor Therapeutics First Quarter 2025 Earnings: US$0.53 loss per share (vs US$0.31 loss in 1Q 2024) - Yahoo Finance
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):